AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34187937 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular Corticosteroid Injection (IACI) with 40mg Triamcinolone and 1ml 2% Lignocaine
Number of subjects: 86
Study 32402160 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus Bevacizumab
Number of subjects: 501
Study 32402160 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 501
Study 33284237 — intervention group
Group type: EXPERIMENTAL
Intervention: nal‐IRI 50 mg/m2 every 2 weeks + TMZ 50 mg/m2/d
Number of subjects: 12
Study 33284237 — intervention group
Group type: EXPERIMENTAL
Intervention: nal‐IRI 70 mg/m2 every 2 weeks + TMZ 50 mg/m2/d
Number of subjects: 12
Study 32355285 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined algorithm for OCT-based drusen quantification
Number of subjects: 0
Study 32355285 — intervention group
Group type: COMPARATOR
Intervention: Replicated algorithm for OCT-based drusen quantification
Number of subjects: 0
Study 32355285 — intervention group
Group type: COMPARATOR
Intervention: Previous algorithm results
Number of subjects: 0
Study 33926519 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics for 4 weeks
Number of subjects: 2000
Study 33926519 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 2000
Study 32085778 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-abdomen (OA) approach with active negative pressure peritoneal therapy
Number of subjects: 0
Study 32085778 — intervention group
Group type: COMPARATOR
Intervention: Standard fascial closure
Number of subjects: 0
Study 32085778 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life measurement using Euroqol EQ-5D-5L and SF-36 surveys
Number of subjects: 0
Study 32085778 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-utility analysis
Number of subjects: 0
Study 32085778 — intervention group
Group type: EXPERIMENTAL
Intervention: Markov modeling for cost per quality-adjusted life years gained
Number of subjects: 0
Study 32085778 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness acceptability curve using Monte Carlo simulation
Number of subjects: 0
Study 32085778 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis for patients with and without septic shock and APACHE II scores
Number of subjects: 0
Study 36474797 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week individualised exercise program combined with behavioural counselling delivered by accredited exercise physiologists
Number of subjects: 63
Study 36474797 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 63
Study 36474797 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week individualised exercise program combined with behavioural counselling
Number of subjects: 63
Study 34663672 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily mobile phone instructional text messages to perform regular outdoor walking and functional leg exercises (n=40)
Number of subjects: 79
Study 34663672 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n=39)
Number of subjects: 79
Study 35499216 — intervention group
Group type: EXPERIMENTAL
Intervention: Telitacicept (80 or 160 mg per week)
Number of subjects: 15
Study 35499216 — intervention group
Group type: EXPERIMENTAL
Intervention: Telitacicept
Number of subjects: 15
Study 34222473 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender aromatherapy
Number of subjects: 150
Study 34222473 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrus aurantium aromatherapy
Number of subjects: 150
Study 34222473 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 150
Study 33186125 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated yoga therapy (performed 3 to 4 times weekly at home with 1 in-office session weekly for the first month)
Number of subjects: 8
Study 33186125 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated yoga therapy
Number of subjects: 8
Study 33947194 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent suction (IS)
Number of subjects: 33
Study 33947194 — intervention group
Group type: COMPARATOR
Intervention: Continuous suction (CS)
Number of subjects: 33
Study 33863679 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM)
Number of subjects: 2123
Study 33863679 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediabetes (Pre-DM)
Number of subjects: 2123
Study 33863679 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 2123
Study 36325594 — intervention group
Group type: EXPERIMENTAL
Intervention: B/myeloid MPALisoMPO
Number of subjects: 13
Study 36325594 — intervention group
Group type: COMPARATOR
Intervention: Other MPAL subtypes
Number of subjects: 13
Study 36325594 — intervention group
Group type: COMPARATOR
Intervention: B-ALL
Number of subjects: 13
Study 34496755 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineural dexamethasone 4 mg with 0.5% ropivacaine
Number of subjects: 0
Study 34496755 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone 4 mg
Number of subjects: 0
Study 34496755 — intervention group
Group type: COMPARATOR
Intervention: No dexamethasone
Number of subjects: 0
Study 33813533 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week multimodal exercise program (MEP) combining physical and cognitive tasks
Number of subjects: 319
Study 33813533 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 319
Study 34343532 — intervention group
Group type: EXPERIMENTAL
Intervention: Early recurrence during the early phase (ER1 group, 0-30 days)
Number of subjects: 2038
Study 34343532 — intervention group
Group type: EXPERIMENTAL
Intervention: Early recurrence during the late phase (ER2 group, 31-90 days)
Number of subjects: 2038
Study 34343532 — intervention group
Group type: COMPARATOR
Intervention: Patients without early recurrences
Number of subjects: 2038
Study 34343532 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with non-paroxysmal atrial fibrillation in the ER2 group
Number of subjects: 2038
Study 36159553 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong (QG) rehabilitation therapy
Number of subjects: 68
Study 36159553 — intervention group
Group type: COMPARATOR
Intervention: Routine cardiologic medication (Control)
Number of subjects: 68
Study 33287570 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuma longa and Boswellia serrata extracts (two tablets twice a day for 1 month)
Number of subjects: 670
Study 35548913 — intervention group
Group type: EXPERIMENTAL
Intervention: tiapride, 100 mg twice daily
Number of subjects: 56
Study 35548913 — intervention group
Group type: COMPARATOR
Intervention: topiramate, 25 mg twice daily
Number of subjects: 56
Study 33148343 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of evidence-based protocols for stroke management in the ED, including triage, administration of tissue plasminogen activator, management of fever, hyperglycaemia, and swallowing, and transfer to a stroke unit.
Number of subjects: 28
Study 33148343 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews with ED and stroke clinicians regarding protocol uptake.
Number of subjects: 28
Study 33148343 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategy for stroke management protocols.
Number of subjects: 28
Study 34241768 — intervention group
Group type: EXPERIMENTAL
Intervention: FCPs delivering vocational advice
Number of subjects: 15
Study 32340616 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated digital reminders + personalized prescribed treatment plan (pPTP)
Number of subjects: 19
Study 32340616 — intervention group
Group type: COMPARATOR
Intervention: SimpleMed+ pillboxes (control group)
Number of subjects: 19
Study 33899302 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity tracker with feedback
Number of subjects: 73
Study 33899302 — intervention group
Group type: COMPARATOR
Intervention: Control (usual encouragement for ambulation)
Number of subjects: 73
Study 35978604 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE plus sorafenib
Number of subjects: 156
Study 35978604 — intervention group
Group type: COMPARATOR
Intervention: TACE alone
Number of subjects: 156
Study 34112266 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic umbilical cord mesenchymal stromal cells (UC-MSCs)
Number of subjects: 53
Study 34112266 — intervention group
Group type: COMPARATOR
Intervention: Standard care based on intensive insulin therapy
Number of subjects: 53
Study 34112266 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic UC-MSCs
Number of subjects: 53
Study 35421015 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook advertising
Number of subjects: 0
Study 35421015 — intervention group
Group type: COMPARATOR
Intervention: Google Ads advertising
Number of subjects: 0
Study 32949255 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous IV butylscopolamine 100 mg/24 h
Number of subjects: 128
Study 32949255 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 128
Study 32007230 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor + Aspirin for 3 months, then Ticagrelor alone for 9 months
Number of subjects: 40
Study 32007230 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel + Aspirin for 3 months, then Clopidogrel alone for 9 months
Number of subjects: 40
Study 32007230 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 40
Study 32007230 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 40
Study 33866968 — intervention group
Group type: EXPERIMENTAL
Intervention: Stay Strong App
Number of subjects: 156
Study 33866968 — intervention group
Group type: COMPARATOR
Intervention: Hep B Story (contact control app)
Number of subjects: 156
Study 33866968 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 156
Study 33866968 — intervention group
Group type: EXPERIMENTAL
Intervention: Stay Strong App (for those with moderate to severe symptoms)
Number of subjects: 156
Study 33866968 — intervention group
Group type: COMPARATOR
Intervention: Hep B Story (for those with moderate to severe symptoms)
Number of subjects: 156
Study 33866968 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D
Number of subjects: 156
Study 33866968 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis attendance
Number of subjects: 156
Study 33512799 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose GLP-2 (1 pmol × kg × min)
Number of subjects: 15
Study 33512799 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose GLP-2 (10 pmol × kg × min)
Number of subjects: 15
Study 33512799 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 15
Study 34245356 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Max Expert White (CMEW)
Number of subjects: 161
Study 34245356 — intervention group
Group type: EXPERIMENTAL
Intervention: Signal Daily White (SDW)
Number of subjects: 161
Study 34245356 — intervention group
Group type: EXPERIMENTAL
Intervention: Himalaya Sparkly White Herbalis (HSWH)
Number of subjects: 161
Study 34245356 — intervention group
Group type: EXPERIMENTAL
Intervention: Signal White System (SWS)
Number of subjects: 161
Study 34245356 — intervention group
Group type: EXPERIMENTAL
Intervention: Rembrandt Deeply White + Peroxide (RDWP)
Number of subjects: 161
Study 34245356 — intervention group
Group type: EXPERIMENTAL
Intervention: Splat Extreme White (SEW)
Number of subjects: 161
Study 34245356 — intervention group
Group type: EXPERIMENTAL
Intervention: Splat White Plus (SWP)
Number of subjects: 161
Study 34245356 — intervention group
Group type: COMPARATOR
Intervention: Kalodont Multi Repair (control)
Number of subjects: 161
Study 32506363 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis (IVT) with idarucizumab reversal in dabigatran-treated patients
Number of subjects: 51
Study 32506363 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical reperfusion (MeR) in patients with large vessel occlusion
Number of subjects: 51
Study 36086723 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (2%) 1.5 mg/kg bolus before induction followed by 2 mg/kg/h continuous infusion up to skin closure
Number of subjects: 60
Study 36086723 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%)
Number of subjects: 60
Study 32992184 — intervention group
Group type: EXPERIMENTAL
Intervention: Local vibration applied to the plantar region for 15 min
Number of subjects: 30
Study 32992184 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no vibration) applied to the plantar region for 15 min
Number of subjects: 30
Study 36326756 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg dose of ERBB2 ICD plasmid-based vaccine
Number of subjects: 66
Study 36326756 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 μg dose of ERBB2 ICD plasmid-based vaccine
Number of subjects: 66
Study 36326756 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg and 500 μg doses of ERBB2 ICD plasmid-based vaccine
Number of subjects: 66
Study 36326756 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest vaccine dose (500 μg)
Number of subjects: 66
Study 34292819 — intervention group
Group type: EXPERIMENTAL
Intervention: Running knotless barbed suture
Number of subjects: 1000
Study 34292819 — intervention group
Group type: COMPARATOR
Intervention: Standard monofilament suture
Number of subjects: 1000
Study 32454356 — intervention group
Group type: EXPERIMENTAL
Intervention: Promoting First Relationships® (PFR), n = 124
Number of subjects: 247
Study 32454356 — intervention group
Group type: COMPARATOR
Intervention: Resource and referral, n = 123
Number of subjects: 247
Study 33616843 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe vera 3% ointment, 1 g twice daily for 6 weeks
Number of subjects: 20
Study 33315181 — intervention group
Group type: EXPERIMENTAL
Intervention: CPC
Number of subjects: 36
Study 33315181 — intervention group
Group type: EXPERIMENTAL
Intervention: PI
Number of subjects: 36
Study 33315181 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 36
Study 33315181 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX
Number of subjects: 36
Study 33710717 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide (14 mg)
Number of subjects: 15
Study 33710717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 35595530 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin
Number of subjects: 0
Study 35595530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35630065 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Number of subjects: 125
Study 35630065 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 125
Study 32055016 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 GyE proton beam therapy (PBT) with intravitreal anti-VEGF therapy
Number of subjects: 30
Study 32055016 — intervention group
Group type: COMPARATOR
Intervention: Sham radiation
Number of subjects: 30
Study 32055016 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 GyE proton beam therapy (PBT)
Number of subjects: 30
Study 35589614 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 354
Study 35589614 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors (meta-analysis)
Number of subjects: 354
Study 35589614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354
Study 33756511 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesamorelin
Number of subjects: 341
Study 33756511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 341
Study 36473929 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized + optimized nutrition (experimental group)
Number of subjects: 91
Study 36473929 — intervention group
Group type: COMPARATOR
Intervention: Optimized nutrition alone (control)
Number of subjects: 91
Study 33290142 — intervention group
Group type: EXPERIMENTAL
Intervention: Cureit supplementation
Number of subjects: 30
Study 35534907 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based cardiac rehabilitation (HBCR) with ICT guidance for 3 months
Number of subjects: 30
Study 35534907 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 30
Study 33444649 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute anorexia nervosa (AN)
Number of subjects: 178
Study 33444649 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term weight restoration
Number of subjects: 178
Study 33444649 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term recovery from AN
Number of subjects: 178
Study 33444649 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity in long-term recovered AN patients
Number of subjects: 178
Study 33444649 — intervention group
Group type: COMPARATOR
Intervention: Healthy control participants
Number of subjects: 178
Study 32468989 — intervention group
Group type: EXPERIMENTAL
Intervention: EXTRAS
Number of subjects: 573
Study 32468989 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 573
Study 32171288 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg QD
Number of subjects: 209
Study 32171288 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib 50 mg QD in 6-week cycles (4 weeks on, 2 weeks off)
Number of subjects: 209
Study 35934637 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-epidermal moisture scanning (SEMS) daily
Number of subjects: 100
Study 35934637 — intervention group
Group type: COMPARATOR
Intervention: Routine pressure injury prevention care and daily visual skin assessment
Number of subjects: 100
Study 32604072 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard warm-up (S-WU)
Number of subjects: 15
Study 32604072 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-minute warm-up at 60% of maximum oxygen uptake (60%-WU)
Number of subjects: 15
Study 32604072 — intervention group
Group type: EXPERIMENTAL
Intervention: No warm-up (No-WU)
Number of subjects: 15
Study 35964100 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chest compression and abdominal compression-decompression CPR (CO-CPR)
Number of subjects: 278
Study 35964100 — intervention group
Group type: COMPARATOR
Intervention: Standard cardiopulmonary resuscitation (STD-CPR)
Number of subjects: 278
Study 34420948 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression stockings (CS) with an interface pressure of 23-32 mmHg
Number of subjects: 0
Study 34420948 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression stockings (CS)
Number of subjects: 0
Study 34420948 — intervention group
Group type: COMPARATOR
Intervention: No compression stockings (without CS)
Number of subjects: 0
Study 35180125 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosgonimeton 40 mg in AD subjects (n=7)
Number of subjects: 88
Study 35180125 — intervention group
Group type: COMPARATOR
Intervention: Placebo in AD subjects (n=4)
Number of subjects: 88
Study 35180125 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosgonimeton (various doses) in healthy young males (n=48)
Number of subjects: 88
Study 35180125 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosgonimeton (various doses) in healthy elderly subjects (n=29)
Number of subjects: 88
Study 35180125 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosgonimeton (various doses)
Number of subjects: 88
Study 35180125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 32190990 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimonthly ranibizumab (0.5 mg intravitreal)
Number of subjects: 306
Study 32190990 — intervention group
Group type: EXPERIMENTAL
Intervention: Treat-and-extend (T&E) ranibizumab (0.5 mg intravitreal)
Number of subjects: 306
Study 32190990 — intervention group
Group type: COMPARATOR
Intervention: Pro re nata (PRN) ranibizumab (0.5 mg intravitreal)
Number of subjects: 306
Study 32190990 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimonthly ranibizumab
Number of subjects: 306
Study 32190990 — intervention group
Group type: EXPERIMENTAL
Intervention: Treat-and-extend (T&E) ranibizumab
Number of subjects: 306
Study 36307008 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridge (person-centered collaborative care)
Number of subjects: 120
Study 36307008 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 120
Study 34078520 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered cryotherapy
Number of subjects: 90
Study 34078520 — intervention group
Group type: COMPARATOR
Intervention: Control (no cryotherapy)
Number of subjects: 90
Study 32058560 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonparametric multivariate analysis of variance with residual randomization in permutation procedures (RRPP)
Number of subjects: 0
Study 35581042 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia combined with erector spinae plane blocks (ESPB)
Number of subjects: 108
Study 35581042 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 108
Study 32554735 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-absorbable sutures
Number of subjects: 192
Study 32554735 — intervention group
Group type: COMPARATOR
Intervention: Absorbable sutures
Number of subjects: 192
Study 35398399 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (PST) for depression
Number of subjects: 26
Study 34193264 — intervention group
Group type: EXPERIMENTAL
Intervention: Melissa officinalis syrup
Number of subjects: 100
Study 34193264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 36039762 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI6012 (2- or 6-dose regimen)
Number of subjects: 593
Study 36039762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 593
Study 36039762 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI6012 (6 doses)
Number of subjects: 593
Study 34753423 — intervention group
Group type: EXPERIMENTAL
Intervention: SCB with mepivacaine 1%, 25-30 ml (n=30)
Number of subjects: 90
Study 34753423 — intervention group
Group type: EXPERIMENTAL
Intervention: SCB with ropivacaine 0.5%, 25-30 ml (n=30)
Number of subjects: 90
Study 34753423 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (GA) with propofol/fentanyl/sevoflurane (n=30)
Number of subjects: 90
Study 32977180 — intervention group
Group type: EXPERIMENTAL
Intervention: Convolutional neural network and image saliency technique for cardiac MRI segmentation
Number of subjects: 85